Government to test remdesivir with Lilly drug in COVID-19 patients

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.’s
GILD,
-0.15%
remdesivir in combination with Eli Lilly & Co.’s
LLY,
+0.35%
rheumatoid arthritis drug Olumiant in COVID-19 patient… [+1273 chars]Source